Avandia

Phase 3Small molecule

GSK

Avandia is one of 81 small molecule programs targeting Insulin resistance. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Insulin ResistanceActive, not recruiting

Glucose IntoleranceActive, not recruiting

HepatitisActive, not recruiting

Insulin ResistancePhase 3

Active, not recruiting

Glucose IntolerancePhase 2

Active, not recruiting

HepatitisPhase 2

Active, not recruiting

Competition

Competitive Landscape

237 competitors in Hepatitis

#DrugCompanyPhaseTrials

Actos

Takeda

Phase 3

4 2

Cysteine Hydrochloride

Novartis

Phase 3

3 3

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

9 4

Crestor

AstraZeneca

Phase 3

1 5

PEG-Intron

Merck & Co.

Phase 3

—6

Aquasol E

NNational Eye Institute (NEI)

Phase 3

2 7

Amoxil

GGlobal Antibiotics Research and Development Partnership

Phase 3

1 8

Rimonabant

Sanofi

Phase 3

1 9

Hepatitis B Vaccine

Sanofi

Phase 3

1 10

Cervarix

GSK

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Insulin resistance1 trial

Study In Patients With Insulin Resistance

Completed· GSK logo

GSK·Phase 3·NCT00197132·18 enrolled

Hepatitis1 trial

Rosiglitazone Versus Rosiglitazone and Metformin Versus Rosiglitazone and Avandia in the Treatment of Nonalcoholic Steatohepatitis (NASH)

Unknown status·—·Phase 2·NCT00699036·165 enrolled

Glucose intolerance1 trial

Rosiglitazone to Treat Patients With Heart Failure and Glucose Intolerance or Type II Diabetes

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT00064727·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Avandia. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Avandia compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Avandia. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: GSK

Avandia

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Insulin resistance1 trial

Hepatitis1 trial

Glucose intolerance1 trial

References

Drug Info

Quick Facts

Related News